MBC Foundation - 2003 Conference Program

2003 Conference

5^th Winter Conference on Medicinal & Bioorganic Chemistry (WCMBC)

January 26 – January 31, 2003
Sheraton Steamboat Springs, Steamboat Springs, Colorado, USA

Conference Program

Sunday | Monday | Tuesday | Wednesday | Thursday | Friday

Sunday, January 26, 2003

1:00pm - Conference Registration – Ballroom Level

4:00 pm - 7:00 pm - Welcome Reception and Super Bowl Party

7:00pm* - Symposium Topic 1: Round Table Discussion on the Foreseeable Future of Medicinal & Bioorganic Chemistry

Session Chair - Gary L. Grunewald, University of Kansas

Paul S. Anderson, retired Vice President Bristol-Myers Squibb and Merck & Company

Lester A. Mitscher, University of Kansas

John G. Topliss, Professor of Medicinal Chemistry, University of Michigan and formerly Vice President of Chemistry at Warner Lambert/Parke-Davis.

* Time subject to minor change due to conclusion of the Super Bowl game.

Monday, January 27, 2003

8:00 am – 11:00 am - Symposium Topic 2: C-H Activation: The New Generation

Session Chair - Victor Snieckus, Queen’s University

Howard Alper, University of Ottawa – "Metal Catalyzed Reactions of
Pharmaceutical Value"

Robert Bergman, University of California, Berkeley - "C-H Activation: The Last Generation Tries to Keep Up with the Next Generation"

John Hartwig, Yale University - "Catalytic Regioselective Functionalization of Alkanes and Arenes with Borane Reagents"

Shinji Murai, Osaka University – "Manipulation of Usually Unreactive C-H bonds for Organic Synthesis"

Victor Snieckus, Queen’s University - "C-H Activation. An Overview"

4:00 pm – 5:00 pm - Poster Session I

Session Chair - Philippe Nantermet, Merck Research Laboratories

5: 00 pm – 8:00pm - Symposium Topic 3: Chemical Genomics in Drug Discovery

Session Chair - Daniel Flynn, Deciphera Pharmaceuticals

Daniel Flynn, Deciphera Pharmaceuticals – "Approaches and Opportunities in Chemical Genomics"

Michael Foley, Infinity Pharmaceuticals, Inc. – "Chemical Genetics"

Mark Murcko, Vertex Pharmaceuticals, Inc. – "Organizing Research by
Gene Family"

Victor G. Matassa, PhD - Graffinity – "Fragment-Based Diversity on Chemical Microarrays - Discovery from a Different Angle"

Tuesday, January 28, 2003

8: 00 am – 11:00 am - Symposium Topic 4: New Developments in High-Throughput Screening Methodologies

Session Chair - Michael Rafferty, Pfizer Global Research & Development
"High Throughput Pharmacology in Drug Discovery"

Sohail A. Qureshi, PhD, PanVera Corporation -
"Cell-Based Assay Development Using GeneDriver"

Huw Nash, NeoGenesis Pharmaceuticals, Inc. - "ALIS: Ultra High Capacity Affinity Screening for Drug Discovery"

Timm Jessen, Evotec OAI - "Increased exploitation of the chemical space through economic sensitivity screening"

5: 00 pm – 8:00 pm - Symposium Topic 5: Innovations in Process & Scale-Up Chemistry

Session Chairs - Tony Barrett, Imperial College and Mike Lipton, Pharmacia Corporation

Robert Osborne, AstraZeneca - "Optimisation by Design"

Shari Taghavi, CPC Germany – "Microreaction Technology, Innovation in Chemical Syntheses from Bench to Production"

Dennis Curran, University of Pittsburgh – "Fluorous Methods in Synthesis of Small Molecules"

Andy de Mello, Imperial College – "Microfluidic Routes to the Controlled Synthesis of Small Molecules"

Peter Wassercheid, University of Aachen, Germany – "Ionic Liquids – A New Concept for Synthesis in Pharmaceutical Chemistry and Fine Chemicals Productions"

Wednesday, January 29, 2003

8: 00 am – 11:00 am - Symposium Topic 6: General Papers I

Session Chair - Michael VanNieuwenhze, University of California, San Diego

12:00 pm - Mountain Lunch at Bashor Picnic Area

Group photo at the Picnic Area

2:00pm - NASTAR Race

6: 00 pm – 11:00 pm - Keynote Address and Banquet

Keynote Speaker - Chi-Huey Wong, The Scripps Research Institute

Thursday, January 30, 2003

8: 00 am – 11:00 am - Symposium Topic 7: General Papers II

Session Chair - Dennis Dean, Merck Research Laboratories

5:00 pm – 8:00 pm - Symposium Topic 8: Chemokine Receptor Antagonists – HIV Targets

Session Chair - Wieslaw M. Kazmierski, GlaxoSmithKline

Nathaniel R. Landau, Ph.D., Infectious Disease Laboratory, The Salk Institute for Biological Studies – "Fusion Inhibitors: Closing the Door on HIV"

Dr. Paul Finke , Department of Medicinal Chemistry, Merck and Co. – "The Development of Potent, Orally Active Antagonists of the Human CCR5 Receptor as Anti-HIV Agents"

Dr. Hiromu Habashita, ONO Pharmaceutical Co., Ltd. , Japan Medicinal Chemistry Research Laboratories - "The Discovery of CCR5 Antagonists from GPCR Targeted Combinatorial Library"

Dr. Jay R. Tagat, Schering-Plough Research Institute - "The Discovery of Potent, Orally Bioavailable CCR5 Antagonists for the Potential Treatment of HIV Infection"

Friday, January 31, 2003

8:00 am – 11:00 am - Symposium Topic 9: Chemokine Receptor Antagonists – Inflammation Targets

Session Chair – Lihu Yang, Merck Research Laboratories

Lihu Yang, Merck & Company – "Chemokine Receptor Antagonism as Potential Therapeutic Targets in Inflammatory Diseases"

Karen May, Berlex Laboratories, Inc
"Discovery of Selective, Potent, Orally Available CCR1 Receptor Antagonists"

Huw Davies, AstraZeneca – "Optimization of Small Molecule CCR2b Antagonists"

Jianming Bao, Merck & Company -
"Pyrrolidine Antagonists of the CCR3 Chemokine Receptors"

Don Hansen, Pharmacia Corporation – "Evolution in Our Design of Selective Inhibitors of Human Nitric Oxide Synthases from Cyclic Amidines to Hybrid Iminohomopiperidinium Amino Acid"

12:00 pm – Conference Closes

The Medicinal and Bioorganic Chemistry Foundation
email: anjanettewilhelm@mindspring.com